BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Municipal officials from across Simcoe-Muskoka met with Royal Victoria Regional Health Centre (RVH) leaders this week to discuss RVH’s vision for the future of health care in the region.

ccf.org Given increased awareness and improved non-invasive diagnostic tools, cardiac amyloidosis has become an increasingly recognised aetiology of increased ventricular wall thickness and heart ...

Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts.

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. University ...